Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $62.25 Consensus PT from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have earned an average rating of “Moderate Buy” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $62.25.

Several analysts have issued reports on the company. Citigroup began coverage on Celldex Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective on the stock. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. Finally, Wolfe Research downgraded shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th.

Celldex Therapeutics Price Performance

Shares of CLDX opened at $25.12 on Friday. The company has a market cap of $1.67 billion, a PE ratio of -9.77 and a beta of 1.57. The firm has a 50-day moving average of $26.31 and a 200-day moving average of $32.93. Celldex Therapeutics has a one year low of $22.93 and a one year high of $53.18.

Insiders Place Their Bets

In related news, CEO Anthony S. Marucci purchased 11,500 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average price of $26.82 per share, with a total value of $308,430.00. Following the completion of the purchase, the chief executive officer now directly owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Celldex Therapeutics

A number of large investors have recently modified their holdings of CLDX. Wellington Management Group LLP grew its holdings in shares of Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock valued at $314,190,000 after purchasing an additional 1,167,659 shares during the last quarter. Bellevue Group AG increased its holdings in shares of Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock worth $104,404,000 after buying an additional 100,000 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Celldex Therapeutics by 51.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after acquiring an additional 654,194 shares during the last quarter. Geode Capital Management LLC grew its position in Celldex Therapeutics by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock worth $52,372,000 after acquiring an additional 6,557 shares during the last quarter. Finally, Marshall Wace LLP increased its holdings in Celldex Therapeutics by 53.3% in the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock worth $50,995,000 after purchasing an additional 479,068 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.